论文部分内容阅读
目的:探讨通心络胶囊联合西洛他唑治疗对气虚血瘀型脑梗死阿司匹林抵抗现象的影响。方法:选取本院收治的68例气虚血瘀型脑梗死阿司匹林抵抗患者为研究对象,按照随机双盲法分为观察组与对照组各34例。观察组给予通心络胶囊联合西洛他唑治疗,对照组仅给予西洛他唑治疗。治疗前后检测和比较2组花生四烯酸(AA)、二磷酸腺苷(ADP)诱导的血小板聚集率和血栓素B2(TXB2)水平。结果:治疗前,2组AA、ADP诱导的血小板聚集率与TXB2水平比较,差异均无统计学意义(P>0.05)。治疗后,2组AA、ADP诱导的血小板聚集率与TXB2水平均较治疗前下降(P<0.05);观察组AA、ADP诱导的血小板聚集率与TXB2水平均低于对照组(P<0.05)。结论:通心络胶囊联合西洛他唑治疗气虚血瘀型脑梗死阿司匹林抵抗可降低患者的血小板聚集率及TXB2水平,且效果优于单纯使用西洛他唑治疗,治疗期间联合用药或单独使用西洛他唑的安全性均较高。
Objective: To investigate the effect of Tongxinluo capsule combined with cilostazol on aspirin resistance in patients with qi deficiency and blood stasis syndrome. Methods: Sixty-eight aspirin-resistant patients with ischemic stroke of qi deficiency and blood stasis type were selected as study subjects and divided into observation group and control group according to randomized double-blind method. The observation group was given Tongxinluo capsule combined with cilostazol, while the control group was given cilostazol only. The levels of platelet aggregation and thromboxane B2 (TXB2) induced by two groups of arachidonic acid (AA) and adenosine diphosphate (ADP) were detected and compared before and after treatment. Results: Before treatment, the platelet aggregation rate induced by AA and ADP was not significantly different from that of TXB2 (P> 0.05). After treatment, the platelet aggregation rate and TXB2 level induced by AA and ADP in both groups were lower than those before treatment (P <0.05). AA and ADP-induced platelet aggregation rate and TXB2 level were lower in the observation group than those in the control group (P <0.05) . Conclusion: Tongxinluo capsule combined with cilostazol can reduce the platelet aggregation rate and TXB2 level in cerebral infarction patients with qi deficiency and blood stasis syndrome, and the effect is better than that of cilostazol alone. The combination of Tongxinluo capsule and cilostazol can reduce the platelet aggregation rate and TXB2 level, Cilostazol safety are higher.